Long-term disease control by trabectedin in a patient with dedifferentiated liposarcoma
Sign Up to like & getrecommendations! Published in 2020 at "Medicine"
DOI: 10.1097/md.0000000000018689
Abstract: Abstract Rationale: Trabectedin is an antitumor drug considered to be effective for liposarcoma, leiomyosarcoma, and translocation-related sarcoma. Concerning liposarcoma subtypes, evidence of the efficacy of trabectedin for dedifferentiated liposarcoma (DDLPS) is poor, whereas it is… read more here.
Keywords: patient; term disease; term; dedifferentiated liposarcoma ... See more keywords
Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study
Sign Up to like & getrecommendations! Published in 2023 at "PLOS ONE"
DOI: 10.1371/journal.pone.0280508
Abstract: Trabectedin is a therapeutic option for patients with advanced sarcoma. While a randomized trial demonstrated its prolonged progression-free survival (PFS), the reported PFS was 1 year). The ORR in the 49 evaluable patients was 8%,… read more here.
Keywords: long term; disease control; term disease;